ILARIS
150mgILARIS150mg
ILARIS (canakinumab) 150mg/ml is a fully human anti-IL-1β monoclonal antibody for treating autoinflammatory diseases including CAPS, SJIA, AOSD, and periodic fever syndromes.
Key Benefits
- Only anti-IL-1β biologic approved for 6+ autoinflammatory indications
- Long half-life (26 days) — dosing every 4-8 weeks vs daily for anakinra
- Fully human monoclonal antibody — low immunogenicity
- Proven cardiovascular benefit in CANTOS trial (15% MACE reduction)
- Pediatric approval from age 2 years for CAPS and SJIA
- Self-administration via subcutaneous injection after training
Contact Us for Pricing
Get competitive wholesale pricing for ILARIS 150mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How ILARIS Works
Canakinumab selectively binds IL-1β with high affinity, preventing it from activating IL-1 receptors. This blocks the downstream inflammatory cascade including NF-κB activation, reducing fever, inflammation, and acute phase reactants (CRP, SAA) within days.
About ILARIS 150mg
ILARIS (canakinumab) 150mg/ml by Novartis is a breakthrough fully human monoclonal antibody that selectively binds and neutralizes interleukin-1 beta (IL-1β), a master pro-inflammatory cytokine driving autoinflammatory cascades. As the only anti-IL-1β biologic with FDA approval across six autoinflammatory indications, Ilaris has transformed treatment of rare inflammatory conditions. FDA-approved for Cryopyrin-Associated Periodic Syndromes (CAPS including FCAS and MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease (AOSD), and Periodic Fever Syndromes (FMF, TRAPS, HIDS/MKD). The CANTOS trial (10,061 patients) also demonstrated cardiovascular benefit, reducing MACE by 15%. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Novartis ILARIS with validated cold chain handling (2-8°C), certificate of authenticity, and competitive wholesale pricing for hospitals, rheumatology clinics, and pharmaceutical distributors worldwide.
Common Uses
- Cryopyrin-Associated Periodic Syndromes (CAPS) — FCAS, MWS
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Adult-Onset Still's Disease (AOSD)
- Familial Mediterranean Fever (FMF)
- TNF Receptor-Associated Periodic Syndrome (TRAPS)
- Hyperimmunoglobulin D Syndrome (HIDS/MKD)
- Gouty arthritis (EMA-approved)
Dosage Information
CAPS: 150mg SC every 8 weeks (adults >40kg), 2mg/kg (15-40kg). SJIA/AOSD: 4mg/kg (max 300mg) SC every 4 weeks. FMF/TRAPS/HIDS: 150mg SC every 4 weeks, may increase to 300mg.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. Keep in original carton. After reconstitution with 1ml sterile water, use within 60 minutes.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About ILARIS
Find answers to common questions about ordering, pricing, and shipping.
Related Rheumatology & Immune Products
Explore more rheumatology & immune medications from our catalog
